Abstract: Provided herein are compositions for reducing regional perineural invasion and pain in a subject. Methods of reducing regional perineural invasion, and associated pain are also described.

Abstract: Provided herein are treatments for improving cancer immunotherapy, and particularly in solid tumors. The described treatments include sustained release oligonucleotide agents, optionally together with immunotherapy agents. Methods of treating cancer with the described treatments are also disclosed.

Abstract: This disclosure relates to RNA interference (RNAi) compositions that target expression of heat shock protein 90 (HSP90) in a subject. Polymeric delivery devices for providing the RNAi compositions are also described, as are methods of treating cancer using the described RNAi compositions.

Abstract: This disclosure relates to RNA interference (RNAi) compositions that target expression of heat shock protein 90 (HSP90) in a subject. Polymeric delivery devices for providing the RNAi compositions are also described, as are methods of treating cancer using the described RNAi compositions.

Abstract: Treatment of prostate cancer by regional and prolonged release of one or more nucleotide-based RNAi agents is provided.

Abstract: Treatment of cancer by regional and prolonged release of one or more nucleotide-based agents is provided.

Abstract: Treatment of cancer by regional and prolonged release of one or more nucleotide-based agents is provided.

Abstract: Treatment of prostate cancer by regional and prolonged release of one or more nucleotide-based RNAi agents is provided.

Abstract: The present invention generally concerns methods and compositions for treating mutated K-ras expressing cancers.

Abstract: Treatment of prostate cancer by regional and prolonged release of one or more nucleotide-based RNAi agents is provided.

Abstract: Implantable medical device eluting drug locally and in a prolonged fashion are provided.

Abstract: The present invention generally concerns methods and compositions for treating mutated K-ras expressing cancers.

Abstract: The present invention generally concerns methods and compositions for treating mutated K-ras expressing cancers.

Abstract: The present invention generally concerns methods and nucleotide-based compositions for treating metastatic cancer that is associated with a primary tumor or a few tumors at the primary organ.

Abstract: The present invention generally concerns methods and compositions for treating mutated K-ras expressing cancers.

Abstract: Treatment of prostate cancer by regional and prolonged release of one or more nucleotide-based RNAi agents is provided.

Abstract: Polymeric implants containing microparticles and nanoparticles, delivery of microparticles and nanoparticles from a polymeric implant is provided.

Abstract: The present invention relates to a system and method for the delivery of a treatment element, and in particular, to such a system and method in which an implantable treatment element is implanted at a target site.

Abstract: Implantable medical device eluting drug locally and in prolonged period is provided, including several types of such a device, the treatment modes of implementation and methods of implantation. The device comprising of polymeric substrate, such as a matrix for example, that is used as the device body, and drugs, and in some cases additional scaffolding materials, such as metals or additional polymers, and materials to enhance visibility and imaging. The selection of drug is based on the advantageous of releasing drug locally and in prolonged period, where drug is released directly to the extracellular matrix (ECM) of the diseased area such as tumor, inflammation, degeneration or for symptomatic objectives, or to injured smooth muscle cells, or for prevention. One kind of drug is the gene silencing drugs based on RNA interference (RNAi), including but not limited to si RNA, sh RNA, or antisense RNA/DNA, ribozyme and nucleoside analogs.